A 32-year-old woman with a history of penicillin allergy presents with a urinary tract infection. She reports a rash following penicillin exposure 5 years ago. Before prescribing a cephalosporin, which investigation is most appropriate to assess the risk of cross-reactivity?

Explanation

## Investigation of Choice for Beta-lactam Cross-Reactivity Risk Assessment ### Clinical Context In patients with reported penicillin allergy, determining the true IgE-mediated allergy and assessing cross-reactivity risk with cephalosporins requires **in vivo allergy testing**. The gold standard approach involves a stepwise protocol: skin prick test (SPT) first, followed by intradermal testing if SPT is negative. ### Why Intradermal Testing with PPL and Major Determinant? **Key Point:** Among the listed options, **intradermal testing with penicilloyl polylysine (PPL) and minor determinants** is the most appropriate and most sensitive investigation for diagnosing IgE-mediated penicillin allergy and guiding cephalosporin use. **High-Yield:** - PPL (penicilloyl polylysine) represents the **major determinant** (~95% of penicillin metabolites) and is the primary sensitizing hapten - Intradermal testing is **more sensitive than skin prick testing alone** — SPT can miss reactions to minor determinants, which are responsible for anaphylaxis in ~15–20% of truly allergic patients - Negative PPL + minor determinant intradermal testing has a **~99% negative predictive value** for IgE-mediated allergy - A negative result allows safe use of cephalosporins (cross-reactivity risk <2% with 3rd-generation cephalosporins) ### Why Not the Other Options? | Option | Limitation | |--------|-----------| | **A) Skin prick test with penicillin G and cephalosporin** | SPT is a valid first-line screen but has **lower sensitivity** than intradermal testing; misses minor determinant reactivity; not sufficient alone as the most appropriate single investigation | | **B) Patch test with amoxicillin** | Patch testing detects **delayed (Type IV) hypersensitivity** — not IgE-mediated allergy; inappropriate for assessing anaphylaxis/cross-reactivity risk | | **D) Serum IgE level measurement** | Total IgE is non-specific; specific anti-penicillin IgE RAST has **low sensitivity (~25%)** and cannot reliably rule out allergy | ### Cross-Reactivity Mechanism | Feature | Penicillins | Cephalosporins | Cross-Reactivity Risk | |---------|-------------|----------------|----------------------| | Beta-lactam ring | Present | Present | Potential | | Side-chain structure | Variable | Different from penicillins | Low (3rd-gen) | | IgE epitope | Penicilloyl-protein | Different structure | <2% (3rd-generation) | **Clinical Pearl:** A rash 5 years ago may represent a delayed hypersensitivity reaction (non-IgE), not true anaphylaxis. Intradermal testing with PPL and minor determinants will clarify the mechanism and guide cephalosporin safety. Skin prick testing alone (Option A) is insufficient because it has lower sensitivity for minor determinants — the very determinants responsible for most anaphylactic reactions. **Mnemonic:** **PPL-SAFE** — PPL intradermal testing provides Safety Assessment For Escalation to cephalosporins. [cite: Harrison's Principles of Internal Medicine, 21e, Ch. 145; KD Tripathi Essentials of Medical Pharmacology, 8e, Ch. 54]